Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from 3D Medicines, Inc. ( (HK:1244) ).
3D Medicines Inc. has successfully administered the first dose of its novel radioactive drug conjugate, 3D1015, in a human trial. This study aims to evaluate the safety and preliminary efficacy of the drug in patients with PSMA-positive metastatic castration-resistant prostate cancer, a group with significant unmet clinical needs. The trial will provide critical clinical evidence for dosage determination and risk management in future clinical trials, potentially impacting the company’s operations and positioning in the oncology drug development market.
The most recent analyst rating on (HK:1244) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.
More about 3D Medicines, Inc.
3D Medicines Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry with a focus on developing innovative drug therapies. The company is engaged in the research and development of novel radioactive drug conjugates, targeting significant unmet clinical needs in the oncology sector.
Average Trading Volume: 594,722
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.05B
Find detailed analytics on 1244 stock on TipRanks’ Stock Analysis page.